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Abstract
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) play critical roles in
female reproduction, while the underlying genetic basis is poorly understood.
Genome-wide association studies (GWASs) of FSH and LH levels were conducted in
2590 Chinese females including 1882 polycystic ovary syndrome (PCOS) cases and
708 controls. GWAS for FSH level identified multiple variants at FSHR showing
genome-wide significance with the top variant (rs2300441) located in the intron of
FSHR. The A allele of rs2300441 led to a reduced level of FSH in the PCOS group
(β = −.43, P = 6.70 × 10−14) as well as in the control group (β = −.35,
P = 6.52 × 10−4). In the combined sample, this association was enhanced after
adjusting for the PCOS status (before: β = −.38, P = 1.77 × 10−13; after: β = −.42,
P = 3.33 × 10−16), suggesting the genetic effect is independent of the PCOS status.
The rs2300441 explained sevenfold higher proportion of the FSH variance than the
total variance explained by the two previously reported FSHR missense variants
(rs2300441 R2 = 1.40% vs rs6166 R2 = 0.17%, rs6165 R2 = 0.03%). GWAS for LH did
not identify any genome-wide significant associations. In conclusion, we identified
genome-wide significant association between variants in FSHR and circulating FSH
first, with the top associated variant rs2300441 might be a primary contributor at the
population level.
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1 | INTRODUCTION
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are
pituitary-secreted gonadotropins that are essential for puberty and fer-
tility in both females and males. Abnormal high FSH level during the
reproductive years is a diagnostic parameter for premature ovarian
failure/aging, while diminished secretion of FSH in combination with
increased LH levels can result in failure of gonadal function manifesting
polycystic ovary syndrome (PCOS), the most common endocrine disor-
der among reproductive age women.1
Twin studies have shown that the heredity of circulating FSH and
LH levels accounted for 50% or more of the phenotype variance.2,3 To
date, five genome-wide association studies (GWASs) for FSH and/or
LH have been conducted,4-7 which have identified three genomic loci
harboring FSHB, CYP19A1, and LHB genes with genome-wide signifi-
cant effects on the circulating LH and/or FSH levels. Candidate gene
studies have found DNA variants within or close to AMH, AMHR2,
CYP19A1, FSHR, FSHB, LHB, MTHFR, SLC18A2, THADA, and VDR genes
showing nominally significant association with FSH and LH levels.8-25
However, these reported variants together could only explain a small
proportion (<3%) of the phenotype variance,4 suggesting that the
genetic basis of FSH and LH is yet poorly understood.
In this study, we conducted the first GWAS for FSH and LH in
Chinese women of Han origin, including 1882 PCOS patients and 708
female controls,26,27 which represent a unique resource for comparing
the genetic effects on FSH/LH in women with and without PCOS.
2 | METHODS
2.1 | Study population
All participants are of Chinese Han origin, including 731 PCOS
patients and 890 female controls individuals as described in our previ-
ous study,26 and additional 1498 PCOS patients described in another
previous study.27 PCOS was diagnosed according to the Revised
2003 Consensus on Diagnostic Criteria and Long-term Health Risks
Related to PCOS.28 Any two of the following three criteria were
required to be met: oligo- and/or anovulation, clinical and/or bio-
chemical signs of hyperandrogenism, and ovarian morphology show-
ing characteristic polycystic features on ultrasound. Other causes of
oligomenorrhea or hyperandrogenism (eg, nonclassical 21-hydroxylase
deficiency, Cushing's syndrome, hyperthyroidism, significant eleva-
tions in serum prolactin) were excluded on clinical grounds. Controls
were gathered primarily from healthy women who presented with
regular menstrual cycles, excluding hyperandrogenism and PCOS. All
individuals who were taking medications such as oral contraceptives
during last 3 months were excluded. Hormone level was drawn on
days 2-4 after menses. FSH and LH levels were measured by a chemi-
luminescent analyzer (Beckman Access Health Company, Chaska,
Minnesota). The study was approved by Institutional Review Board of
Reproductive Medicine Center of Shandong University and written
informed consents were obtained from all subjects.
2.2 | DNA isolation, genotyping, and imputation
Genomic DNA was extracted from ethylene diamine tetraacetic acid-
anticoagulated venous blood samples using Flexi Gene DNA kits
(Qiagen). PCOS patients and control individuals were genotyped using
the Affymetrix Genome-Wide Human SNP Array 6.0 or Axiom
Genome-Wide Arrays. Genotype imputation was conducted using
IMPUTE version 229,30 using the public 1000 Genomes Project Phase
3 imputation panel.31 This panel included 2504 worldwide subjects,
including 504 from East Asians. Imputed SNPs with imputation infor-
mation <80%, MAF <1%, missing rate >3% and HWE <1 × 10−4 were
removed from further analysis. Finally, 3 101 376 genotyped and
imputed SNPs passed the quality control.
2.3 | GWAS analysis
A series of GWASs were conducted separately for FSH and LH and
separately in the PCOS patients, the controls, and in all individuals,
with or without adjusting for the PCOS status. A genomic principal
components analysis (PCA) conducted using pca function in PLINK
V1.9.32 We used unsupervised clustering analysis to cluster the top
main PCAs into three clusters. The GWAS was conducted using linear
regression assuming an additive allele effect and was adjusted for age,
body mass index (BMI), and the top three PCAs using the linear func-
tion in PLINK V1.9. The distributions of the observed P values from
the GWASs were inspected against the null, that is, the uniform distri-
bution between 0 and 1 using Q-Q plots.33 The inflation factor34 was
close to 1.0 (λ < 1.004) in all GWAS and thus not further considered.
GWAS results were visualized using Manhattan plots. The P-values
equal to or smaller than 5e-8 were considered as genome-wide signifi-
cant and equal to or smaller than 1e-5 were considered as genome-
wide suggestive evidence of association. Regional linkage disequilib-
rium (LD) analysis was conducted using the study sample and regional
association plots were produced using LocusZoom.35 Conditional
analysis was carried out for the associated loci by adjusting the geno-
type of the top-associated SNPs. Explained phenotypic variance was
derived for associated SNPs using backward stepwise linear regres-
sion analyses.
2.4 | Function annotation
Potential functions of our GWAS identified SNPs were investigated
using public data downloaded from UCSC, including ChIP-seq of tran-
scription factors and Chromatin state discovery and characterization
(ChromHMM). ChromHMM is an automated computational approach
to segment and annotate the genome, using histone modifications data
from nine cell lines. The target gene of enhancer regions was predicted
by Dragon ENhancers database (DENdb) which defined the nearest
gene of each enhancer by integrating chromatin interaction data.
The Genotype-Tissue Expression project (GTEx)36 data set was
used to annotate our GWAS SNPs for significant cis-eQTL effects
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and expression levels of the identified genes in all available tissues.
The nominal P-value of each variant-gene pair was calculated from
the genome-wide empirical P-value and the beta distribution
model of each gene. The variant-gene pairs with a P-value lower
than the gene-level threshold (0.05 false discovery rate [FDR]) was
considered significant to be included in the list of variant-gene
pairs.
2.5 | Integration with previous association studies
To integrate our findings with the main findings from the previous
FSH and LH GWAS and candidate gene studies, we looked up the
association signals for 11 SNPs reported by previously candidate gene
studies8-24 and four SNPs reported by previous GWAS.4-7,37 Geno-
types of 10 SNPs in AMHR2, CYP19A1, FSHR, FSHB, SLC18A2,
THADA, and VDR genes were available in our samples. Multiple linear
regressions were performed to address the independent effects of the
11 candidate SNPs, while P-values were adjusted for multiple testing
using Bonferroni correction of six LD regions. Adjusted P-value
smaller than or equal to .05 were considered as statistically significant.
All statistical analyses were conducted in R (version 3.4.1) unless oth-
erwise specified.
3 | RESULTS
3.1 | Sample characteristics
This study included 2229 PCOS patients and 890 female controls of
Chinese Han origin. All controls had regular menstrual cycles, without
hyperandrogenism and were on average 2.39 years older than
patients (P < .001). As expected, the PCOS patients had a significantly
increased BMI (P < .001), LH level (P < .001), and testosterone level
(P < .001)), as well as a significantly decreased FSH level (P < .001)
than controls (Table 1).
3.2 | Genome-wide association studies
Unsupervised clustering of genomic PCAs showed that our samples
were clustered together with East Asians and clearly separated from
Europeans and Southern Asians (Figure S1). A set of GWASs for circu-
lating FSH level was separately conducted in 1882 PCOS patients, in
708 controls, and in 2590 combined samples. These GWASs identi-
fied a total of 88 SNPs on 17 loci showing genome-wide suggestive
association (P ≤ 1e-5), among which 14 SNPs in a single genomic
region spanning ~331.8 kb on chromosome 2p16.3 showing genome-
wide significant association (P ≤ 5e-8) with the FSH level (Figure 1A,
B, Figure S2, Table 2, and Table S1). This region harbored five known
genes, including STON1, STON1-GTF2A1L, GTF2A1L, LHCGR, and
FSHR (Figure 1C). The top associated SNP rs2300441 was located in
the intron 8 or 9 of FSHR, and the A allele was associated with a
decreased circulating FSH level. This SNP showed genome-wide sig-
nificant association with FSH in PCOS patients (P = 6.70 × 10−14,
β = −.43 IU/L with 95% CI = −0.31 to −0.55) and nominally significant
association in controls (P = 6.52 × 10−4, β = −.35 IU/L with 95%
CI = −0.15 to −0.55, Table 2). The allele effect in the controls and
PCOS patients are similar, which indicates the association between
rs2300441 and FSH level is independent of PCOS status.
The GWASs in all individuals, with or without adjusting for the
PCOS status, again found the 2p16.3 as the only genome-wide signifi-
cant locus and the rs2300441 being the top-associated SNP. Interest-
ingly, the association signal became more significant after adjusting
for the PCOS status (unadjusted P = 1.77 × 10−13, β = −.38 IU/L with
95% CI = −0.28 to −0.48; adjusted P = 3.33 × 10−16, β = −.42 IU/L
with 95% CI = −0.32-−0.52; Table 2 and Figure S2). These results
strongly suggest that the effect of rs2300441 on FSH levels is inde-
pendent of the PCOS status.
GWASs for LH in the PCOS patients, the controls, and all individ-
uals did not reveal any genome-wide significant associations. The most
significant signal is rs185780876 (P = 3.88 × 10−7) in 720 controls.
3.3 | Conditional analysis and integration with
previous literature
Two missense variants in the exon 10 of FSHR have been reported to
be associated with FSH levels in previous candidate gene studies but
not in GWAS.8-11 These two missense variants also showed genome-
wide significant association with FSH levels in our study (rs6166
P = 7.52 × 10−10 and rs6165 P = 2.67 × 10−9). Conditioning on the
genotype of the top-associated SNP rs2300441, these two missense
variants showed nominally significant residual effects on FSH levels
(rs6165 P = .01; rs6166 P = .002 Figure 1D, Table S2). Further condi-
tioning on the genotype of both rs2300441 and rs6166, no nominally
significant signals were observed in this region (P > .05, Table S2). A
moderate LD between rs2300441 and the two missense variants was
observed (r2 = 0.25) while the LD between rs6165 and rs6166 was
very high (r2 = 0.88). A backward stepwise regression was conducted
to partition the independent contributions of these three variants.
TABLE 1 Characteristics of 3119 female Chinese Han
participants
Characteristics
Controls (N = 890) PCOS patients (N = 2229)
Mean SD Mean SD
Age (years)* 30.69 4.62 28.3 3.62
BMI* 22.68 3.12 24.75 4.01
FSH (IU/L)* 7.54 1.97 6.63 1.68
LH (IU/L)* 4.75 2.08 11.61 5.49
T (ng dL−1)* 36.49 14.02 81.95 18.5
Note: Age of subjects with PCOS was that at diagnosis.
Abbreviations: BMI, body mass index; FSH, follicle-stimulating hormone;
LH, luteinizing hormone; PCOS, polycystic ovarian syndrome; T,
testosterone.
*P < .001.
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The rs2300441 explained the largest proportion of the FSH variance
(rs2300441 R2 = 1.40%), which was sevenfold larger than the com-
bined variance attributable to the two missense variants (rs6166
R2 = 0.17%, rs6165 R2 = 0.03%). These results overall suggest that
rs2300441 and the two missense variants may influence FSH inde-
pendently, while the primary contribution was from rs2300441.
3.4 | Functional annotation
Potential functions of our GWAS identified SNPs were investigated
using multiple types of public data. ChromHMM revealed that four of
our candidate SNPs (rs2072484, rs2072483, rs13032037, and
rs12620721) are contained within enhancers characterized from
F IGURE 1 GWAS analysis for FSH level in 1882 PCOS patients with age and BMI as covariates. A, Manhattan plot for SNPs associated on
FSH level. B, Quantile-quantile plot showing the distribution of expected compared to observed -log10 P for the association test results. C,
Regional Manhattan plots. Chromosome 2p16.3 (48.76-49.60 Mb) containing FSHR. The -log10 P values of all SNPs are plotted against their
physical positions (hg19). Known genes (blue lines) are aligned along their genomic position. At the bottom, the LD structure is shown as obtained
from study samples. Light colors indicate low LD; darker colors indicate high LD. D, Regional Manhattan plots for FSH level conditioned on
rs2300441 (with rs2300441, age, and BMI as covariates). FSH, Follicle-stimulating hormone; GWAS, genome-wide association study; LD, linkage
disequilibrium; PCOS, polycystic ovarian syndrome [Colour figure can be viewed at wileyonlinelibrary.com]
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patterns of histone modifications in GM12878 cell line. This region is
enriched with binding peaks of one transcription factor SPI1. Further-
more, this region was linked to its target gene FSHR by chromatin
interaction assays (DENdb), suggesting a self-regulated pattern. These
findings strongly support a functional role of the 14 GWAS-identified
SNPs (Figure 2A).
The GTEx36 data set was used to annotate our GWAS SNPs for
significant cis-eQTL effects in all available tissues. Among the 14
F IGURE 2 Functional
annotation of candidate
SNPs. A, The upper half part: A
UCSC Genome Browser global
view of FSHR gene. In order,
the features indicate (1) RefSeq
gene, (2) the locations of 14
candidate SNPs, (3) DNase I
hypersensitivity clusters, (4)
conservation scores, (5)
transcription factor ChIP-seq,
and (6) chromatin state
segmentation in three cell lines.
The green box represents a
region located inside one
enhancer in GM12878,
including four SNPs
(rs2072484, rs2072483,
rs13032037, and rs12620721).
The lower half part: Genomic
features of four candidate
SNPs (rs2072484, rs2072483,
rs13032037, and rs12620721).
From top to bottom, the
features shown are (1) RefSeq
gene, (2) the locations of four
candidate SNPs, (3) DNase I
hypersensitivity clusters, (4)
conservation scores, (5)
transcription factor ChIP-seq,
and (6) chromatin state
segmentation in GM12878
(orange and yellow bars are
weak and strong enhancers,
respectively). B,C, FSHR is a
genome-wide significant eQTL
for rs6166 and rs2300441 in
testis. D, FSHR specifically
express in ovary and testis.
Expression values are shown in
transcripts per million (TPM),
calculated from a gene model
with isoforms collapsed to a
single gene. No other
normalization steps have been
applied. Box plots are shown as
median and 25th and 75th
percentiles; points are
displayed as outliers if they are
above or below 1.5 times the
interquartile range [Colour
figure can be viewed at
wileyonlinelibrary.com]
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identified variants, 11 showed significant association with the expres-
sion of FSHR in testis (Table S3) and the most significant SNPs were
rs6166 (P = 9.20E-13) and rs2300441 (P = 1.00 × 10−11). Interest-
ingly, the FSH-reducing A allele of rs2300441 and T allele of rs6166
was associated with an increased expression of FSHR (rs2300441
effect size = 0.41, rs6166 effect size = 0.43; Table S3 and Figure 2B,
C). Moreover, based on GTEx gene expression data, FSHR was
expressed specifically in testis and ovary (Figure 2D). These results
indicated a direct functional link between rs2300441 and FSH action
in gonads although the underlying mechanism needs further study.
3.5 | Candidate gene replication
To integrate our results with the main findings of previous reports, we
looked up the association signals for 10 SNPs in AMHR2, CYP19A1,
FSHR, FSHB, SLC18A2, THADA, and VDR genes from the previous LH
and FSH GWAS (Table S4) and candidate gene studies (Table S5). Pre-
vious GWASs have identified CYP19A1 and FSHB gene variants being
involved in FSH levels,4,6,37 and FSHB and LHB variants involved in LH
levels.4,5,7 In our study, the FSHB variants (rs10835638, rs11031005)
also showed nominally significant effects on FSH level in controls, and
LH level in controls and in the combined samples (P-adjusted < .05,
Table S6) while the SNP at CYP19A1 was not replicated. Previous can-
didate gene studies have suggested a link between LH and FSH levels
and the two missense FSHR variants,8-11 which showed genome-wide
significant association with FSH levels in our GWAS, also showed
nominally significant association with LH levels in the combined sam-
ples (rs6165 and rs6166, P-adjusted <.05, Table S6). The effects of
previously reported gene variants in or close to THADA, SLC18A2, and
VDR were not replicated in our sample (P > .05). Thus, besides the
delivery of a novel variant at FSHR showing genome-wide significant
association with FSH, we confirmed the effect of the variants at FSHR
and FSHB gene variants on both FSH and LH levels as suggested in
previous candidate gene studies.
3.6 | Discussion
In our study, the 2p16.3 FSHR region showed genome-wide signifi-
cant association with FSH level in Han Chinese women. This locus has
also been reported to be associated with multiple sex hormone
related phenotypes in previous GWAS studies. For example, our pre-
vious GWAS, which contained the samples of the current study iden-
tified two different SNPs at the FSHR gene region showing significant
association with PCOS risk.27 A previous GWAS in 22 000 Europeans
identified several different SNPs in the same region showing sugges-
tive association with sex hormone-binding globulin concentrations.38
This locus has also been suggested as a susceptibility locus for erectile
dysfunction, although was not replicated by Bovijn et al.39,40 There-
fore, multiple lines of evidence in population samples, together with
our findings, underlie the important role of FSHR in sex hormone gen-
esis. The failure of detecting the FSHR association with FSH levels in
previous GWAS4,6,37 could be due to several factors, such as sample
size, sample demographic characteristics, and population
heterogeneity.
Two missense variants in the exon 10 of FSHR (rs6165,
Thr307Ala, and rs6166, Asn680Ser) have been associated with FSH
levels in previous candidate gene studies.8-11 We also replicated their
effects with genome-wide significant evidence in our GWAS. These
two variants in the key domain of FSHR play important roles in FSH
efficacy.41 In our study, the top-associated SNP rs2300441 is located
in the intron 8 or 9 of FSHR. Our data highlight that the effect of
rs2300441 was independent of rs6165 and rs6166. In addition, the
effect of rs2300441 was much stronger than those of rs6165 and
rs6166 in a multivariable model. It is possible that rs2300441 has
effects on FSHR expression or action, resulting in a need for altering
FSH levels to stimulate the receptor for follicle growth.
In GTEx, FSHR was an eQTL of rs2300441 meeting genome-wide
significance in testis but is not significant in ovary. Since FSHR is spe-
cifically expressed in ovarian granulosa cells, further experiments in
granulosa cells are needed to confirm the association of rs2300441
and the expression of FSHR.42
FSHR SNPs have been correlated with ovarian reserve and
response. Mutations and variants of FSHR were considered as a risk
factor for ovarian hyperstimulation syndrome occurrence in assisted
reproduction techniques (ARTs).43 FSH and FSHR might affect con-
trolled ovarian stimulation in ART and consequently assisted repro-
duction outcome.43,44 Combination of FSHR genotype and other risk
factors may provide a mean of predicting ovarian response to FSH or
chance of pregnancy before in vitro fertilization procedures are initi-
ated.45,46 Variant rs2300441 identified in this study could be a poten-
tial marker for ovarian response and reproduction outcome in ARTs.
4 | CONCLUSIONS
In conclusion, the variant rs2300441 in FSHR showed a genome-wide
significant effect on FSH levels in both PCOS patients and female
controls of Chinese Han origin. The effect of rs2300441 on FSH
levels was independent of PCOS status and the two previously
reported FSHR missense variants.
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